[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349763-105":59,"doc-detail-349763-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","characterization-of-the-immunogenomic-landscape-of-ovarian-cancer-uncovers-a-distinct-subset-of-endometroid-tumors-associated-with-high-cst2-expression-and-a-favorable-prognosis","Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High CST2 Expression and a Favorable Prognosis","","Ovarian cancers with similar histopathology can show diverse immunogenomic profiles that may require different treatment strategies. Using a multimodal latent variable model, the study integrates somatic mutation, mRNA expression, and multiplex immunofluorescence data across 197 patients to map intertumor heterogeneity. Gene expression and immune infiltration in tumor core and invasive margin are key drivers, largely independent of histologic subtype. A distinct endometrioid subgroup with high CST2 expression shows improved prognosis, with collagen-related programs linked to tumor microenvironmental inflammation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/characterization-of-the-immunogenomic-landscape-of-ovarian-cancer-uncovers-a-distinct-subset-of-endometroid-tumors-associated-with-high-cst2-expression-and-a-favorable-prognosis/349763/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/characterization-of-the-immunogenomic-landscape-of-ovarian-cancer-uncovers-a-distinct-subset-of-endometroid-tumors-associated-with-high-cst2-expression-and-a-favorable-prognosis/349763.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-18","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What approach did the study use to analyze ovarian cancer immunogenomic differences?","Question",{"text":112,"@type":113},"It applied a multimodal latent variable model integrating somatic mutation, mRNA expression, and multiplex immunofluorescence data across 197 patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which factors primarily drive immunogenomic heterogeneity between ovarian tumors?",{"text":117,"@type":113},"The majority of heterogeneity is driven by gene expression and immune infiltration in the tumor core and invasive margin.",{"name":119,"@type":110,"acceptedAnswer":120},"What distinguishes the endometrioid ovarian cancer subgroup identified by the analysis?",{"text":121,"@type":113},"A distinct endometrioid subgroup is characterized by increased CST2 expression and an improved prognosis, along with additional immunogenomic features.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349763,1790219010,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-25-0150](https://doi.org/10.1158/2767-9764.CRC-25-0150)  OPEN ACCESS  \nCharacterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High CST2 Expression and a Favorable Prognosis  \nJames Boyle1, Jan Zaucha1, Felicia Ng1, Andreas Spitzmller2, Miljenka Vuko2, Felix J. Segerer2,  \nMonica Azqueta-Gavaldon2, Marco Testori2, Amelia Raymond3, Barrett R. B. Nuttall3, Andrea Ennio Storti4, Sakshi Gulati5, Shaan Gill6, Michael Surace7, Paola Marco-Casanova6, Emma V. Jones6, Ben S. Sidders1, Jorge S. Reis-Filho8, Maurizio Scaltriti7, Anita Semertzidou6, and Helen K. Angell6  \n􀀶  \nABSTRACT  \nOvarian cancers with similar histopathologic but diverse immunogenomic profiles may require different treatment regimens to achieve the best clinical outcomes. The development of optimal treatment regimens will thus require an understanding of the main ways in which ovarian cancers differ with respect to their immunogenomic profiles. We used a multimodal latent variable model to enable an integrated analysis of somatic mutation, mRNA expression, and multiplex immunofluorescence data to uncover the principal drivers of intertumor heterogeneity across 197 patients with ovarian cancer. We found that the majority of the immunogenomic intertumor heterogeneity was driven by gene expression and immune infiltration in the tumor core and invasive margin. Moreover, much of this heterogeneity could not be explained by histologic subtype; somatic mutation patterns explained much of the difference between high-grade serous and other subtypes. Clustering of samples according to their positions in the latent space revealed a distinct subgroup of endometrioid ovarian cancer tumors, characterized by increased CST2 expression and improved prognosis, among other immunogenomic features. We identified a group of collagen-related genes, for which  \nexpression in all subtypes was inversely correlated with the density of proliferating tumor cells in the tumor core and associated with increased levels of inflammatory fibroblasts, independent of tumor purity. In summary, our findings advocate for a paradigm shift in how we classify and approach the treatment of ovarian cancer. By moving beyond the constraints of histologic subtypes and delving into the molecular intricacies of patient-specific tumor microenvironments, we unveil a new opportunity for targeted immunooncological treatment of a subset of patients with ovarian cancer.  \nSignificance: Our study employs a multimodal latent variable model across 197 patients to identify principal drivers of immunogenomic intertumor heterogeneity. We uncover a distinct subgroup of endometrioid ovarian cancer with a unique immunogenomic signature and better prognosis and a set of collagen-related genes associated with the tumor microenvironment. This work challenges the adequacy of existing histologic classifications in capturing the molecular diversity of ovarian cancer, potentially informing more personalized treatment strategies.  \n1Oncology Data Science, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. 2Computational Pathology GmbH, AstraZeneca, Munich, Germany. 3Translational Medicine, Oncology R&D, AstraZeneca, Boston, Massachusetts. 4Oncology Data Science Platforms, Oncology R&D, AstraZeneca, Munich, Germany. 5Oncology Data Science Platforms, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. 6Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. 7Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, Maryland. 8Cancer Biomarker Development, Oncology R&D, AstraZeneca, Gaithersburg, Maryland.  \nA. Semertzidou and H.K. Angell contributed equally as senior authors and jointly supervised this work.  \nCorresponding Author: Anita Semertzidou, AstraZeneca, Biomedical Campus, 1 Francis Crick Ave, Trumpington, Cambridge CB2 0AA, United Kingd","cbCaiiIUJtpa3Vk4","https://ap.wps.com/l/cbCaiiIUJtpa3Vk4","pdf",3807474,11,"English","# Abstract\n## Study approach (multimodal latent variable modeling)\n## Key findings (drivers of heterogeneity, CST2 subgroup)\n## Biological mechanisms (collagen-related genes and microenvironment)","[{\"question\":\"What approach did the study use to analyze ovarian cancer immunogenomic differences?\",\"answer\":\"It applied a multimodal latent variable model integrating somatic mutation, mRNA expression, and multiplex immunofluorescence data across 197 patients.\"},{\"question\":\"Which factors primarily drive immunogenomic heterogeneity between ovarian tumors?\",\"answer\":\"The majority of heterogeneity is driven by gene expression and immune infiltration in the tumor core and invasive margin.\"},{\"question\":\"What distinguishes the endometrioid ovarian cancer subgroup identified by the analysis?\",\"answer\":\"A distinct endometrioid subgroup is characterized by increased CST2 expression and an improved prognosis, along with additional immunogenomic features.\"}]","Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High CST2 Expression and a Favorable Prognosis | PDF",1790085435,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/67308b9c13faaa372475609e941f35c0.webp",983,1263,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/630326a77c671fd0d3cb29f10df3f551.webp",982,1262,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88387404d1d0af3b8b359c64602c2900.webp",981,1261,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ec273d4f033b2a7c578dd78aa2b7e64f.webp",980,1259]